PORTFOLIO NEWS Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 14, 2022 Read More » Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in November 10, 2022 Read More » RAPT Therapeutics Reports Third Quarter 2022 Financial Results November 10, 2022 Read More » Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update November 10, 2022 Read More » Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies November 10, 2022 Read More » eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 7, 2022 Read More » ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update November 7, 2022 Read More » Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress November 7, 2022 Read More » A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022 November 7, 2022 Read More » NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results November 3, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 14, 2022 Read More »
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in November 10, 2022 Read More »
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update November 10, 2022 Read More »
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies November 10, 2022 Read More »
eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 7, 2022 Read More »
ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update November 7, 2022 Read More »
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress November 7, 2022 Read More »
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022 November 7, 2022 Read More »
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results November 3, 2022 Read More »
